[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

OneMedNet Corporation (Nasdaq: ONMD) filed an 8-K detailing a series of equity and debt restructuring transactions completed between 17-20 June 2025.

• $2.5 million private placement: 3,390,923 common shares and pre-funded warrants for 2,561,457 shares were sold to an accredited investor at $0.42 per share. Warrants are immediately exercisable at $0.0001. A voting agreement binds the investor to Board recommendations. The company will register the resale shares via an S-1 amendment.
• Insider subscriptions: Director Dr. Thomas Kosasa invested $0.5 million for 1,190,476 shares; CMO/Chairman Dr. Jeffrey Yu invested $0.7 million for 1,666,666 shares, both at $0.42.
• Loan conversions: • $3.3 million of shareholder loans (Kosasa $2.0 m, Yu $1.3 m) converted into 4,693,299 shares at $0.71.
  • Kosasa elected to convert an additional $1.6 million of convertible loans into 2,123,424 shares at $0.7535.
  • Holders of $1.66 million PIPE Notes converted into 1,453,174 shares at $1.14.
• Liability settlement: The company settled ~$4.34 million of trade payables, including $2.76 million deferred underwriter fees. It also redeemed the remaining $250,000 balance of a Yorkville promissory note for cash.

In aggregate, ONMD raised $3.7 million in new equity capital and eliminated or converted approximately $11 million of current liabilities—representing a 60 % reduction relative to 31 March 2025. However, the transactions add roughly 17 million new or issuable shares, materially increasing outstanding share count and potential dilution. Net proceeds are earmarked for general corporate purposes and working capital.

Insights

Financial Analyst

TL;DR – Cash inflow and 60 % liability reduction improve balance sheet, but heavy low-price share issuance is dilutive; net effect neutral.

The company’s immediate liquidity strengthens: $3.7 million gross cash plus potential receipts if pre-funded warrants are exercised. Eliminating $11 million of obligations (loans, trade payables, PIPE, Yorkville) sharply de-levers the balance sheet ahead of Q2 close. These actions may lower future interest expense and remove going-concern pressure.
Dilution is significant. Including warrants, ~17 million incremental shares could expand the float well above 100 % of the 16.0 million shares reported outstanding at 31 Mar 2025, pressuring per-share metrics. Pricing at $0.42–$1.14 was below historical SPAC trust value, indicating limited bargaining power. Insider participation signals confidence yet also concentrates ownership. Overall, financial posture stabilises, but EPS accretion is unlikely; I view the impact as balanced.

Corporate Governance Specialist

TL;DR – Insider funding and investor voting pact tighten Board control; governance implications modestly positive.

Directors Kosasa and Yu injected $1.2 million and converted $4.6 million of loans, aligning insider capital with shareholder outcomes. The voting agreement obliges the private placement investor to support Board recommendations, reducing proxy contest risk during a pivotal restructuring phase. Required resale registration demonstrates transparency and may aid liquidity. While concentration of voting power could limit minority influence, the strengthened insider commitment and simplified capital structure after debt conversions enhance governance stability. I assign a +1 impact.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July, 2025

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                 Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                        No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated July 02, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED
	(Registrant)
Date: July 02, 2025	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

FAQ

How much cash did OneMedNet (ONMD) raise in the June 2025 private placement?

The company raised approximately $2.5 million by selling 3,390,923 shares and pre-funded warrants at $0.42 per share.

What is the total reduction in OneMedNet’s liabilities from the reported transactions?

Management states that about $11.0 million of current liabilities were settled or converted, a 60 % reduction versus 31 March 2025.

How many new shares could be issued as a result of the transactions?

Roughly 17 million shares, including common stock, warrant shares, and conversion shares, will be added to the outstanding share count.

Why are insiders Dr. Kosasa and Dr. Yu significant in these transactions?

They invested a combined $1.2 million in new equity and converted over $3.3 million in loans, indicating confidence and reducing company debt.

What is the exercise price of the pre-funded warrants issued on 19 June 2025?

The pre-funded warrants are exercisable immediately at $0.0001 per share, effectively prepaid except for a nominal amount.

Will the newly issued shares be registered for resale?

Yes. ONMD agreed to file an amendment to its latest Form S-1 to register the resale of all shares issued or issuable under these transactions.